CORRECTED VERSION

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 10 February 2005 (10.02.2005)

PCT

(10) International Publication Number WO 2005/011642 A1

(51) International Patent Classification7: A61K 9/52, 9/36

(21) International Application Number:

PCT/BE2004/000111

(22) International Filing Date: 4 August 2004 (04.08.2004)

(25) Filing Language:

English

(26) Publication Language:

English

5 August 2003 (05.08.2003)

(71) Applicant (for all designated States except US): GALE-PHAR M/F [BE/BE]; Rue du Parc Industriel 39, B-6900

- (30) Priority Data:
 PCT/BE03/00132 5 Augu

 (71) Applicant (for all designated PHAR M/F [BE/BE]; Rue du Marche-en-Famenne (BE).

 (72) Inventors; and
 (75) Inventors/Applicants (for US Francis [BE/BE]; Alsembergs Beersel (BE). BAUDIER, Ph. geland 338, B-1180 Uccle (B [BE/US]; HCO2 Box 14885, G (US). SERENO, Antonio [BE/F Melsbroeck (BE).

 (74) Agents: POWIS DE TENBOSS inet Bede, Boulevard General W. (BE).

 (81) Designated States (unless other kind of national protection availa

 (57) Abstract: An oral lipid lowering phorate and a second and lipid lowering phorate and lipid lowering lipid lipid lowering lipid lipid lowering lipid (75) Inventors/Applicants (for US only): VANDERBIST, Francis [BE/BE]; Alsembergsesteenweg 1116, B-1650 Beersel (BE). BAUDIER, Philippe [FR/BE]; Rue Engeland 338, B-1180 Uccle (BE). DEBOECK, Arthur [BE/US]; HCO2 Box 14885, Gurabo, Puerto Rico 00778 (US). SERENO, Antonio [BE/BE]; Passiewyk 21, B-1820
 - (74) Agents: POWIS DE TENBOSSCHE, Roland et al.: Cabinet Bede, Boulevard General Wahis 15, B-1030 Bruxelles
 - (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, **ZW**.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of
- (48) Date of publication of this corrected version:

1 December 2005

(15) Information about Correction:

see PCT Gazette No. 48/2005 of 1 December 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SINGLE UNIT PHARMACEUTICAL COMPOSITION COMPRISING A MIXTURE OF A FIBRATE AND AN HO-

(57) Abstract: An oral lipid lowering pharmaceutical unit form comprising a first solid or semi solid composition comprising fenofibrate and a second solid or semi solid composition comprising at least a modified release form of an homocysteine lowering agent.